PPT-Decompensated cirrhosis Clinical Practice Guidelines

About these slides These slides give a comprehensive overview of the EASL clinical practice guidelines on the management of decompensated cirrhosis The guidelines were first presented at the International Liver Congress 2018 and are published in the Journal of Hepatology. Cirrhosis is caused by chronic longterm liver diseases that damage liver tissue Chronic alcoholism and chronic hepatitis C are the leading causes of cirrhosis Nonalcoholic steatohepatitis NASH bile duct disease and genetic diseases can also lead KNH 411. Morgan . Deihs. Lydia Dysart. Objectives. Define Cirrhosis . Understand what MELD means. Name 3 SYMPTOMS of Cirrhosis. Name 3 Methods of TREATMENT for Cirrhosis. Background. Teresa (Terri) Wilcox:. AYURVEDIC . TREATMENT . Dr. . Vikram. . Chauhan. is One of the most . Promising . Ayurvedic. doctors in the world. and a senior consultant physician from India. . He has 12 years of international exposure & . Co-formulated . ombitasvir. (OBV)/. paritaprevir. (PTV)/. rironavir. (r) :. 25/150/100 mg QD = 2 tablets. Dasabuvir. (DSV) : 250 mg bid. Objective. SVR. 12. (HCV RNA < 25 IU/ml). TURQUOISE-III . SIRIUS. Phase . 2 . Treatment. . Experienced. Bourliere. M, et al. Lancet Infect Dis. . 2015;15:397-404.. Source: . Bourliere. . M, . et al. . Lancet Infect Dis. 2015;15:397-404.. Ledipasvir-Sofosbuvir in Treatment-Experienced . ). The liver is vulnerable to a wide variety of metabolic, toxic, microbial, circulatory, and neoplastic insults. . The major primary diseases of the liver are viral hepatitis, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, and hepatocellular carcinoma (HCC).. Kings College Hospital London UK. . 20–50%. . <1.0%. . 2–3%. . 7–8%. . 3–5%. . 2–6% for HBeAg+. . 20–50%. <0.2%. . 8–10% for HBeAg-. HBV-related liver disease progression. TREATMENT . Dr. . Vikram. . Chauhan. is One of the most . Promising . Ayurvedic. doctors in the world. and a senior consultant physician from India. . He has 12 years of international exposure & . Best Practices & Overcoming Obstacles. Richard . Rosenfeld, SUNY Downstate. Peter Robertson and Stephanie Jones, AAO-HNS. The American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS) is the world's largest organization representing specialists who treat the ear, nose, throat, and related structures of the head and neck. . Nowlan Selvapatt. Consultant Hepatologist. Imperial College Healthcare NHS Trust . Overview. Understanding the scale of the problem. Brief overview of referral pathways. Diagnostics in Primary Care. Nicholas Lim, MD. Associate Professor of Medicine. Alaska Tribal Health Webinar Series. May 5. th. 2022. Disclosures. No Financial Relationships. No Discussion of Off-label Medication Use or Investigational Drugs. ASTRAL-4. Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.. Treatment Naïve and Treatment Experienced, Phase 3. Sofosbuvir-Velpatasvir in Decompensated HCV Cirrhosis. ASTRAL-4: Study Features. Chris Kolkman. PrimaryOne. Health. Meet MM. Patient Background. MM is a 59-year-old Hispanic female who presents for a regular health checkup, accompanied by her daughter to help translate. . CC: “I would like to establish care here in the US and to have someone manage my diabetes and cirrhosis.”. SOLAR-2. Source: . Manns. M, et al. Lancet Infect Dis. 2016;16:685-97.. Treatment Naïve and Treatment Experienced, Phase 2. Ledipasvir-Sofosbuvir + Ribavirin in Advanced Liver Disease. SOLAR-2: Features.